GQEBERHA, South Africa (Reuters) - South Africa's Aspen Pharmacare is aiming to ramp up its COVID-19 vaccine manufacturing capacity to 1.3 billion doses a year by February 2024, up from annual output of around 250 million doses now, the company's CEO told Reuters.
Aspen is doing the final stages of manufacturing for Johnson & Johnson's COVID-19 vaccine in a so-called "fill and finish" deal, but CEO Stephen Saad said in an interview that the companies were close to announcing a broader deal for Aspen to produce Johnson & Johnson's COVID-19 shot under licence.
(Reporting by Promit Mukherjee; Writing by Alexander Winning; Editing by Jon Boyle)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 448.1 PTS | -0.37% | -1.57% | - | ||
| 151.6 PTS | +0.08% | -1.31% | - | ||
| 1,934 PTS | +0.67% | -0.99% | - | ||
| 216.7 ZAR | -0.13% | -3.18% | 5.03B | ||
